DelveInsight’s “Stress Urinary Incontinence Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Stress Urinary Incontinence market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Stress Urinary Incontinence drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Stress Urinary Incontinence treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Stress Urinary Incontinence: An Overview
Stress urinary incontinence (SUI) is when urine comes out with sudden pressure on the bladder and urethra, causing the sphincter muscles to open briefly. In mild SUI, pressure can come from sudden violent activities such as moving, sneezing, laughing, or coughing, and in severe cases, it can come from less vigorous activities such as standing, walking, or bending over. International Continence Society (ICS) identifies several urinary incontinence (UI) subtypes: urgency urinary incontinence (UUI), stress UI (SUI), and mixed UI (MUI)
SUI can occur when the pelvic tissues and muscles that support the bladder and urethra weaken and sink around the bladder neck (where the bladder and urethra intersect) during physical activity. Even the weakened sphincter muscle cannot stop the flow of urine under normal circumstances and with increased abdominal pressure. The weakness can occur from pregnancy, childbirth, aging, or previous pelvic surgery. Other risk factors for SUI include chronic or exertional cough, obesity, and smoking.
Urine samples to detect infections, blood traces, or other abnormalities, brief neurological examination to identify, urinalysis, cystoscopy, pelvic nerve problems, urinary stress test, and bladder function test are some of the common diagnostic methods.
Women have surgical and non-surgical options to treat SUI. Pelvic floor exercises, pessaries, transurethral fillings, and behavior modification are the preferred options during the non-surgical process whereas the surgical process includes Retropubic suspension, Sling procedure, and Artificial sphincters. There are no approved medications to specifically treat stress incontinence in the United States. The antidepressant duloxetine (Cymbalta, Drizalma Sprinkle) is used for the treatment of stress incontinence in Europe.
Stress Urinary Incontinence Market Key Facts
-
As per Rubilotta et al., (2019) study, Stress Urinary Incontinence was present in 59.4% of patients. The prevalence of clinical P-SUI was 20.7%, while the prevalence of complicated SUI (C-SUI) was 79.3% in USA women.
-
Stress urinary incontinence was the most common type of incontinence, while 10% of the women had symptoms of voiding dysfunction (Cooper et al., 2014).
-
As per Rubilotta et al., (2019) study, stress urinary incontinence (SUI) was present in 59.4% of patients. The prevalence of clinical P-SUI was 20.7%, while the prevalence of complicated SUI (C-SUI) was 79.3% in USA women.
-
In the US, the prevalence of Stress urinary incontinence (SUI) is variably estimated to affect between 4% and 35% of adult women.
-
Stress urinary incontinence affects 15.7% of adult women; 77.5% of women report the symptoms to be bothersome and 28.8% report the symptoms to be moderate to severe Lugo and Riggs (2021).
-
In men, the prevalence of incontinence is much lower than in women, about 3% to 11% overall, with urge incontinence accounting for 40% to 80% of all male patients. Stress incontinence accounts for less than 10% of cases and is attributable to prostate surgery, trauma, or neurological injury.
Stress Urinary Incontinence Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Stress Urinary Incontinence pipeline therapies. It also thoroughly assesses the Stress Urinary Incontinence market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Stress Urinary Incontinence drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Stress Urinary Incontinence Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Stress Urinary Incontinence epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Stress Urinary Incontinence epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Stress Urinary Incontinence Epidemiology, Segmented as –
-
Prevalent Cases of Stress Urinary Incontinence (SUI) in 7MM [2019–2032]
-
Gender-Specific Prevalent Cases of Stress Urinary Incontinence (SUI) in 7MM [2019–2032]
-
Diagnosed and Treatable Cases of Stress Urinary Incontinence (SUI) in the 7MM [2019–2032]
-
Cause-specific Cases of Stress Urinary Incontinence (SUI) in 7MM [2019–2032]
-
Age-Specific Prevalent Cases of Stress Urinary Incontinence (SUI) in 7MM [2019–2032]
Stress Urinary Incontinence Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Stress Urinary Incontinence market or expected to be launched during the study period. The analysis covers the Stress Urinary Incontinence market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Stress Urinary Incontinence drugs based on their sale and market share.
The report also covers the Stress Urinary Incontinence pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Stress Urinary Incontinence companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Stress Urinary Incontinence Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/stress-urinary-incontinence-market
Stress Urinary Incontinence Therapeutics Analysis
There are several treatment options for SUI available, and treatment of stress incontinence depends on how severe the symptoms are and how much they affect day-to-day life. The five most common treatment options for Stress Urinary Incontinence (SUI) are Behavior Changes, Kegel exercises, Vaginal Pessary, Urethral Bulking Agents, and Surgery. Pharmacological options for the treatment include Oxybutynin, Tricyclic anti-depressants, and Estrogen Lugo, and Riggs (2021).
The Stress Urinary Incontinence (SUI) market dynamics are anticipated to change in the coming years owing to the expected launch of emerging therapies such as TAS-303, Gefapixant. The launch of various multiple-stage pipeline products will significantly revolutionize Stress Urinary Incontinence shortly.
Stress Urinary Incontinence Companies Actively Working in the Therapeutics Market Include
-
Taiho Pharmaceutical Co. Ltd.
-
Merck Sharp & Dohme Corp.
And Many Others
Emerging and Marketed Stress Urinary Incontinence Therapies Covered in the Report Include:
-
TAS-303: Taiho Pharmaceutical Co. Ltd.
-
Gefapixant: Merck Sharp & Dohme Corp.
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/stress-urinary-incontinence-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Stress Urinary Incontinence Competitive Intelligence Analysis
4. Stress Urinary Incontinence Market Overview at a Glance
5. Stress Urinary Incontinence Disease Background and Overview
6. Stress Urinary Incontinence Patient Journey
7. Stress Urinary Incontinence Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Stress Urinary Incontinence Treatment Algorithm, Current Treatment, and Medical Practices
9. Stress Urinary Incontinence Unmet Needs
10. Key Endpoints of Stress Urinary Incontinence Treatment
11. Stress Urinary Incontinence Marketed Therapies
12. Stress Urinary Incontinence Emerging Drugs and Latest Therapeutic Advances
13. Stress Urinary Incontinence Seven Major Market Analysis
14. Attribute Analysis
15. Stress Urinary Incontinence Market Outlook (In US, EU5, and Japan)
16. Stress Urinary Incontinence Companies Active in the Market
17. Stress Urinary Incontinence Access and Reimbursement Overview
18. KOL Views on the Stress Urinary Incontinence Market
19. Stress Urinary Incontinence Market Drivers
20. Stress Urinary Incontinence Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/stress-urinary-incontinence-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Homozygous Familial Hypercholesterolemia Market
“Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Homozygous Familial Hypercholesterolemia market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research